Your session is about to expire
What is Qsymia
PhentermineThe Generic name of this drug
Treatment SummaryPhentermine is a drug used to help people lose weight by reducing appetite. It was introduced in 1959 and is classified as a Schedule IV drug, meaning it has a low potential for abuse. It is related to amphetamine but does not have the same addictive qualities. Phentermine was initially combined with other drugs to create an anti-obesity regime, but was later approved as a stand-alone drug in 2012. It is typically used in short-term weight management programs and is taken in lower doses than when it was combined with other drugs.
Ionaminis the brand name
Qsymia Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ionamin
Phentermine
1959
298
Approved as Treatment by the FDA
Phentermine, also known as Ionamin, is approved by the FDA for 3 uses including Obesity and Comorbidity .Obesity
Used to treat Obesity in combination with Topiramate
Comorbidity
Used to treat one related comorbidity in combination with Topiramate
Regime of weight reduction
Effectiveness
How Qsymia Affects PatientsPhentermine is thought to work by reducing appetite and increasing the body's resting energy expenditure. In clinical studies, patients taking phentermine lost an average of 3.6 kg over two to twenty-four weeks and were able to maintain their weight after treatment stopped. Unlike other drugs in the amphetamine family, phentermine does not cause any stimulation of the central nervous system, high blood pressure, tolerance or QTc prolongation.
How Qsymia works in the bodyPhentermine is a medication that helps reduce hunger by increasing levels of noradrenaline in the brain. This causes the body to enter a state of alertness, which suppresses the feeling of hunger. It also weakly inhibits monoamine oxidase, although this effect is not usually significant.
When to interrupt dosage
The measure of Qsymia is contingent upon the specified disorder, comprising Regime of weight reduction, Hyperlipidemia and Type 2 Diabetes. The amount likewise deviates as per the technique of delivery (e.g. Oral or Tablet) articulated in the table hereunder.Condition
Dosage
Administration
Type 2 Diabetes
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
, Oral, Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Obesity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
, Oral, Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Caloric Restriction
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
, Oral, Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Hypertensive disease
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
, Oral, Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
High Cholesterol
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
, Oral, Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Regime of weight reduction
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
, Oral, Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Chronic Weight Management therapy
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
, Oral, Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
increase in physical activity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
, Oral, Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Comorbidity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
, Oral, Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Warnings
Qsymia has seven forbidden contraindications, so it is not advised to take Qsymia when suffering from any of the conditions in the below table.Qsymia ContraindicationsCondition
Risk Level
Notes
Hyperthyroidism
Do Not Combine
concomitant use or 14 days after discontinuation
Do Not Combine
Agitation
Do Not Combine
Drug abuse
Do Not Combine
Cardiovascular Diseases
Do Not Combine
Open-angle glaucoma
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Phentermine may interact with Pulse Frequency
Common Qsymia Drug Interactions
Drug Name
Risk Level
Description
Iobenguane
Major
Phentermine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylene blue
Major
Phentermine may increase the serotonergic activities of Methylene blue.
Mirtazapine
Major
Phentermine may increase the serotonergic activities of Mirtazapine.
1-benzylimidazole
Minor
The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Phentermine.
4-Methoxyamphetamine
Minor
The risk or severity of hypertension can be increased when Phentermine is combined with 4-Methoxyamphetamine.
Qsymia Toxicity & Overdose RiskThe toxic dose of phentermine for rats is 151mg/kg. Signs of an overdose may include restlessness, tremors, rapid breathing, confusion, aggression, hallucinations, and panic followed by fatigue and depression. It can also cause irregular heartbeat, high or low blood pressure, stomach issues such as nausea, vomiting, and abdominal cramps. Chronic overdosing may lead to skin problems, difficulty sleeping, irritability, hyperactivity, and changes in personality. In severe cases, it may cause a psychosis similar to schizophrenia. Carcinogenic or mutagenic effects have not been observed.
Qsymia Novel Uses: Which Conditions Have a Clinical Trial Featuring Qsymia?
There are 104 active studies investigating the potential of Qsymia to treat Type 2 Diabetes, facilitate Weight Reduction Regimens and ameliorate Disease.Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
86 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Obesity
0 Actively Recruiting
Hypertensive disease
0 Actively Recruiting
Comorbidity
0 Actively Recruiting
High Cholesterol
12 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Early Phase 1
Caloric Restriction
0 Actively Recruiting
Regime of weight reduction
0 Actively Recruiting
increase in physical activity
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting
Qsymia Reviews: What are patients saying about Qsymia?
5Patient Review
9/13/2022 I've been on this medication for six months and have lost 50 pounds. I started at 208 and was considered obese; now I'm just overweight with a BMI of 28. I'm still taking the medication and planning to lose 25 more pounds.
4.7Patient Review
4/29/2022 I'm really happy with this medication. I've been able to keep the weight off that I lost, and my cravings are mostly under control.
4.7Patient Review
10/29/2021 I've been seeing some great results. I lost 25 pounds in the first three weeks while taking this medication. I'm currently still on the 7mg dose and have experienced some fatigue; however, I believe this could be my body getting used to the medicine. Overall, I'm pleased with how things are going and plan to continue using this treatment.
4Patient Review
5/14/2022 This pill is working great for me! I started it last Sunday and by the following Saturday, I had lost 9 pounds. I'm going on vacation in 20 days and need to lose 10 pounds to hit my weight goal, so this is perfect. I'm currently taking 15 mg per day and am down to 140 pounds from 149.
4Patient Review
12/8/2021 I started this treatment two days ago and have had headaches that I hope will go away. I've been looking online to see if anyone else has experienced this symptom and whether or not it goes away. I'm hopeful that this works because my hip is in terrible shape and I've gained a lot of weight because my mobility is so limited.
Patient Q&A Section about qsymia
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Qsymia stronger than phentermine?
"There are no studies that compare phentermine and topiramate directly, but experts believe that topiramate is a stronger weight loss medication than phentermine alone."
Answered by AI
What are side effects of Qsymia?
"You may experience dizziness, drowsiness, a dry mouth, difficulty sleeping, tiredness, tingling in your hands and feet, constipation, or a metallic taste. If any of these effects last longer than a few days or get worse, tell your doctor or pharmacist."
Answered by AI
How fast do you lose weight on Qsymia?
"My results have been good. I lost 25 pounds in the first 3 weeks - two weeks while taking 3.5mg of the medication and one week while taking 7mg of the medication."
Answered by AI
How does Qsymia work for weight loss?
"Phentermine is a drug that causes an immediate response, while Topiramate works throughout the day. The combination of the two drugs helps to reduce your levels of hunger and promote weight loss more effectively than diet and exercise alone. On average, people who take these drugs lose 5-8.9% of their excess body weight."
Answered by AI